Darya-Varia Laboratoria Tbk PT
IDX:DVLA
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 390
1 810
|
| Price Target |
|
We'll email you a reminder when the closing price reaches IDR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Darya-Varia Laboratoria Tbk PT
Darya-Varia Laboratoria Tbk PT
Accrued Liabilities
Darya-Varia Laboratoria Tbk PT
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Darya-Varia Laboratoria Tbk PT
IDX:DVLA
|
Accrued Liabilities
Rp372.3B
|
CAGR 3-Years
9%
|
CAGR 5-Years
8%
|
CAGR 10-Years
17%
|
|
|
T
|
Tempo Scan Pacific Tbk PT
IDX:TSPC
|
Accrued Liabilities
Rp146B
|
CAGR 3-Years
19%
|
CAGR 5-Years
8%
|
CAGR 10-Years
4%
|
|
|
Kalbe Farma Tbk PT
IDX:KLBF
|
Accrued Liabilities
Rp630.5B
|
CAGR 3-Years
7%
|
CAGR 5-Years
8%
|
CAGR 10-Years
7%
|
|
|
Soho Global Health Tbk PT
IDX:SOHO
|
Accrued Liabilities
Rp174.4B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
Pyridam Farma Tbk PT
IDX:PYFA
|
Accrued Liabilities
Rp98.5B
|
CAGR 3-Years
101%
|
CAGR 5-Years
89%
|
CAGR 10-Years
48%
|
|
|
Kimia Farma Tbk PT
IDX:KAEF
|
Accrued Liabilities
Rp513.5B
|
CAGR 3-Years
59%
|
CAGR 5-Years
28%
|
CAGR 10-Years
24%
|
|
Darya-Varia Laboratoria Tbk PT
Glance View
PT Darya-Varia Laboratoria Tbk engages in the manufacture and trade of pharmaceutical products and cosmetics. The company is headquartered in Jakarta, Dki Jakarta and currently employs 1,274 full-time employees. Its segments include prescription drugs, consumer health products, and export and toll manufacturing services. The firm provides products and services for consumer health, skin nutrition, respiratory, vitamins and daily relief. The Company’s products include Remscar (silicone gel), Carvilol, Ondavar (antiemetic), Etorix, Forti-D (vitamin D supplement), Decolgen, Neozep, Stop Cold, Decolsin, and Allerin. The Carvilol is used for heart health and treating hypertension. Ondavar is an antiemetic product used for nausea and vomiting during pregnancy. Etorix is a pain reliever. Forti-D is a supplement to fulfill the body’s need for vitamin D3. Darya-Varia provides a range of brands such as Enervon-C, Enervon Active, and Supertin that helps to boost body immune and maintain health. The firm also provides Imunped as supplement for kids with Zinc and vitamin C for children.
See Also
What is Darya-Varia Laboratoria Tbk PT's Accrued Liabilities?
Accrued Liabilities
372.3B
IDR
Based on the financial report for Sep 30, 2024, Darya-Varia Laboratoria Tbk PT's Accrued Liabilities amounts to 372.3B IDR.
What is Darya-Varia Laboratoria Tbk PT's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 10Y
17%
Over the last year, the Accrued Liabilities growth was 50%. The average annual Accrued Liabilities growth rates for Darya-Varia Laboratoria Tbk PT have been 9% over the past three years , 8% over the past five years , and 17% over the past ten years .
You don't have any saved screeners yet
